# Key References

Core literature supporting the VDAC1 Gate-Opening Therapeutic Stack (SAD v4.0).

References organized by the mechanistic evidence chain (Table 3, SAD v4.0).

---

## Core Mechanism: Statin-Mediated Cholesterol Depletion (Lock 3)

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Montero et al.** *Cancer Research* (2008) | Elevated mitochondrial cholesterol confers chemotherapy resistance in HCC | Strong |
| **Huang et al.** *Antioxidants (Basel)* 13(6):679 (2024) | Lovastatin induces mtDNA release + cGAS-STING activation in HCT116 CRC cells and xenografts | Strong |
| **Shen et al.** *eLife* (2024) | Statins specifically reduce mitochondrial membrane cholesterol | Strong |
| **Betaneli et al.** *Biophysical Journal* (2012) | Cholesterol rigidifies OMM, disfavors VDAC1 oligomeric transitions | Strong |

## Gate-Opening Physics: VDAC1 Oligomerization and mtDNA Release

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Shoshan-Barmatz et al.** (multiple) | VDAC1 oligomerization forms ~4 nm pore; basis for GJS cofactor equation | Strong |
| **Kim et al.** *Science* (2019) | mtDNA escapes through VDAC1 oligomeric pores (500-650 bp fragments) | Strong |

## Innate Immune Ignition: cGAS-STING Pathway

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Li & Chen** (2018) | cGAS-STING pathway: cytosolic DNA sensing to IFN-B production | Strong |
| **West et al.** (2015) | mtDNA as endogenous STING ligand activating innate immunity | Strong |

## Clinical Validation: Statin + ICI Combination

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Liao et al.** *JCO Oncology Practice* (2025) | Meta-analysis (n=46,154): statin + ICI = 20% all-cause mortality reduction | Strong (meta) |
| **Stokes et al.** *J ImmunoTherapy of Cancer* (2023) | Statins enhance PD-1 blockade via T-cell activation + M2-to-M1 macrophage repolarization in HNSCC | Strong |

## Cavalry Drug Selection: Botensilimab

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Vidal et al.** *Nature Medicine* (2024) | Botensilimab + balstilimab achieves 17-20% ORR in MSS CRC (Phase I) | Moderate (Phase I) |

## Pathway B Amplification: CoQ10 / ROS

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Huang et al.** *Antioxidants* (2024) | Lovastatin depletes CoQ10 biosynthesis, increases mitochondrial ROS, amplifies cholesterol depletion effect | Moderate |

## TSPO / Fourth Lock (Exploratory)

| Citation | Finding | Relevance |
|----------|---------|-----------|
| **Gatliff et al.** *Autophagy* (2014) | TSPO physically binds VDAC1 on OMM; TSPO:VDAC1 ratio modulates signaling | Fourth lock candidate |
| **Maaser et al.** *Clinical Cancer Research* (2002/2005) | TSPO overexpression in 28% CRC; mean survival 56.2 vs 86.8 months (p=0.03) | Prognostic marker |
| **Banati et al.** *Nature Communications* (2014) | TSPO knockout mice viable, fertile, normal lifespan | Safety profile |
| **Zhang et al.** *Advanced Science* (2023) | PK11195 + anti-PD-1 synergistic anti-tumor effects in HCC | Combination precedent |
| **Tu et al.** *Endocrinology* (2015) | PK11195 off-target effects persist in TSPO-KO | Selectivity caution |
| **Fu et al.** *Neuro-Oncology* (2020) | TSPO-KD paradoxically promotes glioblastoma growth | Directionality caution |

## CBD Quarantine Evidence

| Citation | Finding | Relevance |
|----------|---------|-----------|
| **Sido et al.** (2016) | CBD suppresses CD8+ T-cell proliferation and cytokine production at 5-10 uM | Quarantine Basis 1 |
| **Kaplan et al.** (2003) | CBD immunosuppressive at concentrations overlapping VDAC1-active doses | Quarantine Basis 1 |
| **ESMO 2024 interim** (NCT03944447) | CBD + nivolumab 10.7% ORR in MSS CRC, not clearly superior to nivolumab alone | Quarantine Basis 2 |
| **Ibeas Bih et al.** (2015) | CBD affects over 65 molecular targets; mechanism specificity concern | Quarantine Basis 3 |
| **Nelson et al.** *J Medicinal Chemistry* (2020) | CBD colloidal aggregation concern at >10 uM | Specificity caution |
| **Bar-Sela et al.** | Cannabis users: OS 6.4 vs 28.5 months with immunotherapy | Clinical signal |
| **Catherall et al.** *MCP* (2022) | Cholesterol disruption potentiates CBD-induced apoptosis | Possible late-stage role |

## Falsification Sources (Killed Original Hypothesis)

| Citation | What It Killed | Implication |
|----------|---------------|-------------|
| **Jimenez-Loygorri et al.** *Nature Communications* (2024) | TSPO-mitophagy-mtDNA pathway | Mitophagy clears mtDNA, doesn't release it |
| **Bakhoum et al.** *Cancer Discovery* (2020) | Chronic cGAS-STING as therapeutic | Chronic activation is immunosuppressive in CRC |
| **Sliter et al.** (2018) | Mitophagy as mtDNA release mechanism | Mitophagy role is clearance, not release |
| **Wang et al.** *Autophagy* (2025) | Mitophagy and mtDNA dynamics | Further confirms clearance role |

## Supplementary / Cholesterol Biology

| Citation | Finding |
|----------|---------|
| **Montero et al.** *Cancer Research* (2008) | Elevated mitochondrial cholesterol confers chemotherapy resistance |

---

*Total unique citations: ~30 | Last updated: February 2026 (SAD v4.0)*
